A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy
Clinical trial NCT06945107 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06945107
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-27
- Primary completion
- 2026-06-07
- Enrollment
- 308
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.